Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636422 | 0.97 | — | — | |
| SCHEMBL1164553 | 0.86 | KDM4E (0.34) | KDM4EALDH1A1 | |
| SCHEMBL1343696 | 0.86 | KDM4E (0.34) | KDM4EALDH1A1 | |
| SCHEMBL45941 | 0.86 | KDM4E (0.34) | KDM4EALDH1A1 | |
| SCHEMBL6618 | 0.86 | — | — | |
| SCHEMBL28386367 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL1200019 | 0.82 | — | — | |
| Ammonia Solution, Strong SCHEMBL16007514 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL5048648 | 0.79 | — | — | |
| SCHEMBL1002987 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673892-B2 | Bicyclic compounds for use as RIP1 kinase inhibitors | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| CN-110650959-B | Therapeutic compounds and compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-3694858-B1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-01-11 | — | — | EP | disclosed |
| US-20200352951-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200283446-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | GENENTECH, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3694858-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2020-08-19 | — | — | EP | disclosed |
| EP-3630766-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2020-04-08 | — | — | EP | disclosed |
| CN-110650959-A | Therapeutic compounds and compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-20190240227-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| WO-2019072942-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| WO-2018215389-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-11-29 | — | — | WO | disclosed |
| US-20180333416-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333416-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KDM4E 1122/4885ALDH1A1 2575/4885 |
| US-20190240227-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KDM4E 2075/4885ALDH1A1 2322/4885 |
| US-20200352951-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KDM4E 1834/4885ALDH1A1 2746/4885 |
| US-20200283446-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | KDM4E 1698/4885ALDH1A1 3998/4885 |
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | JAK2, JAK1, JAK3 | KDM4E 1122/4885ALDH1A1 2575/4885 |
| US-11673892-B2 | Bicyclic compounds for use as RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | KDM4E 1698/4885ALDH1A1 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.